Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes-Reference-Cited by-同舟云学术

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

Published:2018-10-05 Issue:4 Volume:60 Page:517-523
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Violet John,Jackson Price,Ferdinandus Justin,Sandhu Shahneen,Akhurst Tim,Iravani Amir,Kong Grace,Kumar Aravind Ravi,Thang Sue Ping,Eu Peter,Scalzo Mark,Murphy Declan,Williams Scott,Hicks Rodney J.,Hofman Michael S.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference50 articles.

1. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

2. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy

3. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

4. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer

5. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer;Ross;Clin Cancer Res.,2003

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards personalized patient 3D Monte Carlo dosimetry for Lu-177-psma prostate treatments;Radiation Physics and Chemistry;2024-10

2. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

3. Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer;Journal of Nuclear Medicine;2024-08-14

4. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

5. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07